<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03709823</url>
  </required_header>
  <id_info>
    <org_study_id>ACH-CYT-09</org_study_id>
    <nct_id>NCT03709823</nct_id>
  </id_info>
  <brief_title>Trial of Cytisine in Adult Smokers</brief_title>
  <official_title>A Multicenter, Double-blind, Randomized, Placebo-controlled Phase 2b Trial of Cytisine in Adult Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Achieve Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Achieve Life Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This placebo-controlled Phase 2b trial is being conducted at sites within the United States
      (US) to evaluate the effectiveness cytisine dosage (1.5 mg, 3.0 mg) and administration
      schedule (commercial titration versus simplified 3 times daily [TID] schedule) within a
      25-day treatment period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 13, 2018</start_date>
  <completion_date type="Actual">April 23, 2019</completion_date>
  <primary_completion_date type="Actual">April 23, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Efficacy Analysis of Primary Outcome Measure: Percentage of Expected Cigarettes Smoked Per Participant During Study Treatment</measure>
    <time_frame>Day 1 through Day 25</time_frame>
    <description>The daily cigarette counts (number of cigarettes smoked in the past 24 hours) were self-reported by participants in the diary. Percentage of expected cigarettes smoked was computed for each participant at the end of treatment (cigarette score), based on daily cigarette counts during treatment vs the screening period. The percentage of expected cigarettes smoked was computed as Y = (100 x N) / (T x R) where N represents total number of cigarettes smoked each day over the treatment period from Day 1 to Day 25; T represents number of post-randomization days where number of cigarettes smoked is recorded; and R represents the average number of cigarettes smoked daily over the 7-day screening period as baseline. T*R represents the total number of cigarettes that would have been smoked without intervention over the number of recorded days. Separate statistical analyses were performed for the two cytisine administration schedules (commercial and TID).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitivity Analysis of Primary Outcome Measure: Analysis for Percentage of Expected Cigarettes Smoked Versus Pooled Placebo Arms, Commercial Schedule</measure>
    <time_frame>Day 1 through Day 25</time_frame>
    <description>The daily cigarette counts (number of cigarettes smoked in the past 24 hours) were self-reported by participants in the diary. Percentage of expected cigarettes smoked was computed for each participant at the end of treatment (cigarette score), based on daily cigarette counts during treatment vs the screening period. (See Outcome Measure 1 description for details.) The sensitivity analysis of the primary outcome measure was only performed if results of &quot;Statistical Analysis 5&quot; for Outcome Measure 1 demonstrated the placebo treatment arms (commercial and TID) were not significantly different, and so could be pooled. Separate statistical analyses were performed for the two cytisine administration schedules (commercial and TID).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitivity Analysis of Primary Outcome Measure: Analysis for Percentage of Expected Cigarettes Smoked Versus Pooled Placebo Arms, TID Schedule</measure>
    <time_frame>Day 1 through Day 25</time_frame>
    <description>The daily cigarette counts (number of cigarettes smoked in the past 24 hours) were self-reported by participants in the diary. Percentage of expected cigarettes smoked was computed for each participant at the end of treatment (cigarette score), based on daily cigarette counts during treatment vs the screening period. (See Outcome Measure 1 description for details.) The sensitivity analysis of the primary outcome measure was only performed if results of &quot;Statistical Analysis 5&quot; for Outcome Measure 1 demonstrated the placebo treatment arms (commercial and TID) were not significantly different, and so could be pooled. Separate statistical analyses were performed for the two cytisine administration schedules (commercial and TID).</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">254</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>1.5 mg Cytisine, Commercial Schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 mg cytisine dose using the commercial 25-day titration schedule + behavioral support</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.0 mg Cytisine, Commercial Schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.0 mg cytisine dose using the commercial 25-day titration schedule + behavioral support</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Commercial Schedule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets using the commercial 25-day titration schedule + behavioral support</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.5 mg Cytisine, TID Schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 mg cytisine dose for 25 days using a simplified 3 times daily (TID) schedule + behavioral support</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.0 mg Cytisine, TID Schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.0 mg cytisine dose for 25 days using a simplified TID schedule + behavioral support</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, TID Schedule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets for 25 days using a simplified TID schedule + behavioral support</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytisine</intervention_name>
    <description>film coated tablet containing 1.5 mg cytisine in a single tablet</description>
    <arm_group_label>1.5 mg Cytisine, Commercial Schedule</arm_group_label>
    <arm_group_label>1.5 mg Cytisine, TID Schedule</arm_group_label>
    <arm_group_label>3.0 mg Cytisine, Commercial Schedule</arm_group_label>
    <arm_group_label>3.0 mg Cytisine, TID Schedule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>1.5 mg cellulose powder to match final weight of the cytisine tablet</description>
    <arm_group_label>Placebo, Commercial Schedule</arm_group_label>
    <arm_group_label>Placebo, TID Schedule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral support</intervention_name>
    <description>12 behavioral support sessions by a qualified staff member plus supportive literature and online resources</description>
    <arm_group_label>1.5 mg Cytisine, Commercial Schedule</arm_group_label>
    <arm_group_label>1.5 mg Cytisine, TID Schedule</arm_group_label>
    <arm_group_label>3.0 mg Cytisine, Commercial Schedule</arm_group_label>
    <arm_group_label>3.0 mg Cytisine, TID Schedule</arm_group_label>
    <arm_group_label>Placebo, Commercial Schedule</arm_group_label>
    <arm_group_label>Placebo, TID Schedule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects, age ≥ 18 years.

          2. Current daily cigarette smokers (averaging ≥ 10 cigarettes per day upon completing a
             7-day screening diary) and who intend to quit smoking.

          3. Expired air carbon monoxide (CO) ≥ 10 parts per million (ppm).

          4. Failed at least one previous attempt to stop smoking with or without therapeutic
             support.

          5. Willing to initiate study treatment on the day after randomization and set a quit date
             that is 5-7 days after starting treatment.

          6. Willing to actively participate in the study's smoking cessation behavioral support
             provided throughout the study.

          7. Able to fully understand all study requirements, willing to participate, comply with
             dosing schedule, and sign the Informed Consent Form.

        Exclusion Criteria:

          1. Known hypersensitivity to cytisine or any of the excipients.

          2. Positive urinary drugs of abuse screen, determined within 28 days before the first
             dose of cytisine.

          3. Clinically significant abnormal serum chemistry or hematology values within 28 days of
             randomization (i.e. requiring treatment).

          4. Clinically significant abnormalities in 12-lead electrocardiogram (ECG) determined
             after minimum of 5 minutes in supine position within 28 days of randomization (i.e.
             requiring treatment or further assessment).

          5. Body mass index (BMI) classification for being underweight (&lt; 18.5 kg/m^2) or having ≥
             Class 2 obesity (≥ 35 kg/m^2).

          6. Recent history (within 3 months) of acute myocardial infarction, unstable angina,
             stroke, cerebrovascular incident or hospitalization for congestive heart failure.

          7. Current uncontrolled hypertension (blood pressure ≥ 160/100 mmHg).

          8. Documented diagnosis of schizophrenia or bipolar psychiatric illness; currently
             psychotic; having suicidal ideation (Suicide Behaviors Questionnaire-Revised [SBQ-R]
             score ≥ 7); or current symptoms of moderate to severe depression (Hospital Anxiety and
             Depression Scale [HADS] score ≥ 11).

          9. Renal impairment defined as a creatinine clearance (CrCl) &lt; 60 mL/min (estimated with
             the Cockroft-Gault equation) or hepatic impairment defined as alanine aminotransferase
             (ALT) or aspartate aminotransferase (AST) &gt; 2.0 times the upper limit of normal (ULN).

         10. Women who are pregnant or breast-feeding.

         11. Male or Female subjects of child bearing potential who do not agree to use acceptable
             methods of birth control during the study treatment period.

         12. Participation in a clinical study with an investigational drug within 4 weeks of
             randomization.

         13. Treatment with other smoking cessation medications (bupropion, varenicline,
             nortriptyline, or any nicotine replacement therapy [NRT]) within 4 weeks of
             randomization or planned use of these other smoking cessation medications during the
             study.

         14. Use within 2 weeks of randomization or planned use during the study of non-cigarette
             nicotine products (e-cigarettes, pipe tobacco, cigars, snuff, chewing tobacco, hookah)
             or marijuana vaping or smoking.

         15. Any other reason that the investigator views the subject should not participate or
             would be unable to fulfill the requirements for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell Nides, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Los Angeles Clinical Trials</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Consortium</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Los Angeles Clinical Trials</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Kentucky Research Associates, LLC</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Pharmaceutical Research, LLC</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research, Inc</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center, Inc</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volunteer Research Group</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FutureSearch Trails of Dallas, LP</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>57231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 15, 2018</study_first_submitted>
  <study_first_submitted_qc>October 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2018</study_first_posted>
  <results_first_submitted>April 16, 2020</results_first_submitted>
  <results_first_submitted_qc>April 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 30, 2020</results_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 15, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT03709823/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 29, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT03709823/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1.5 mg Cytisine, Commercial Schedule</title>
          <description>1.5 mg cytisine dose using the commercial 25-day titration schedule + behavioral support</description>
        </group>
        <group group_id="P2">
          <title>3.0 mg Cytisine, Commercial Schedule</title>
          <description>3.0 mg cytisine dose using the commercial 25-day titration schedule + behavioral support</description>
        </group>
        <group group_id="P3">
          <title>Placebo, Commercial Schedule</title>
          <description>Placebo tablets using the commercial 25-day titration schedule + behavioral support</description>
        </group>
        <group group_id="P4">
          <title>1.5 mg Cytisine, TID Schedule</title>
          <description>1.5 mg cytisine dose for 25 days using a simplified 3 times daily (TID) schedule + behavioral support</description>
        </group>
        <group group_id="P5">
          <title>3.0 mg Cytisine, TID Schedule</title>
          <description>3.0 mg cytisine dose for 25 days using a simplified TID schedule + behavioral support</description>
        </group>
        <group group_id="P6">
          <title>Placebo, TID Schedule</title>
          <description>Placebo tablets for 25 days using a simplified TID schedule + behavioral support</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="52"/>
                <participants group_id="P5" count="50"/>
                <participants group_id="P6" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="50"/>
                <participants group_id="P5" count="49"/>
                <participants group_id="P6" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other, Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1.5 mg Cytisine, Commercial Schedule</title>
          <description>1.5 mg cytisine dose using the commercial 25-day titration schedule + behavioral support</description>
        </group>
        <group group_id="B2">
          <title>3.0 mg Cytisine, Commercial Schedule</title>
          <description>3.0 mg cytisine dose using the commercial 25-day titration schedule + behavioral support</description>
        </group>
        <group group_id="B3">
          <title>Placebo, Commercial Schedule</title>
          <description>Placebo tablets using the commercial 25-day titration schedule + behavioral support</description>
        </group>
        <group group_id="B4">
          <title>1.5 mg Cytisine, TID Schedule</title>
          <description>1.5 mg cytisine dose for 25 days using a simplified TID schedule + behavioral support</description>
        </group>
        <group group_id="B5">
          <title>3.0 mg Cytisine, TID Schedule</title>
          <description>3.0 mg cytisine dose for 25 days using a simplified TID schedule + behavioral support</description>
        </group>
        <group group_id="B6">
          <title>Placebo, TID Schedule</title>
          <description>Placebo tablets for 25 days using a simplified TID schedule + behavioral support</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="52"/>
            <count group_id="B5" value="50"/>
            <count group_id="B6" value="26"/>
            <count group_id="B7" value="254"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.8" spread="11.46"/>
                    <measurement group_id="B2" value="50.0" spread="13.20"/>
                    <measurement group_id="B3" value="51.0" spread="15.16"/>
                    <measurement group_id="B4" value="47.0" spread="13.67"/>
                    <measurement group_id="B5" value="46.3" spread="12.88"/>
                    <measurement group_id="B6" value="47.0" spread="12.64"/>
                    <measurement group_id="B7" value="48.4" spread="13.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="133"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="41"/>
                    <measurement group_id="B6" value="18"/>
                    <measurement group_id="B7" value="200"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="46"/>
                    <measurement group_id="B5" value="49"/>
                    <measurement group_id="B6" value="26"/>
                    <measurement group_id="B7" value="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Average Number of Cigarettes Smoked per Day Over 7 Consecutive Days</title>
          <description>As reported in the participant’s 7-day diary, which was completed between screening visits 1 and 2.</description>
          <units>cigarettes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.6" spread="5.30"/>
                    <measurement group_id="B2" value="18.0" spread="5.51"/>
                    <measurement group_id="B3" value="16.7" spread="4.28"/>
                    <measurement group_id="B4" value="18.0" spread="6.69"/>
                    <measurement group_id="B5" value="18.0" spread="6.12"/>
                    <measurement group_id="B6" value="18.0" spread="5.96"/>
                    <measurement group_id="B7" value="17.8" spread="5.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Efficacy Analysis of Primary Outcome Measure: Percentage of Expected Cigarettes Smoked Per Participant During Study Treatment</title>
        <description>The daily cigarette counts (number of cigarettes smoked in the past 24 hours) were self-reported by participants in the diary. Percentage of expected cigarettes smoked was computed for each participant at the end of treatment (cigarette score), based on daily cigarette counts during treatment vs the screening period. The percentage of expected cigarettes smoked was computed as Y = (100 x N) / (T x R) where N represents total number of cigarettes smoked each day over the treatment period from Day 1 to Day 25; T represents number of post-randomization days where number of cigarettes smoked is recorded; and R represents the average number of cigarettes smoked daily over the 7-day screening period as baseline. T*R represents the total number of cigarettes that would have been smoked without intervention over the number of recorded days. Separate statistical analyses were performed for the two cytisine administration schedules (commercial and TID).</description>
        <time_frame>Day 1 through Day 25</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg Cytisine, Commercial Schedule</title>
            <description>1.5 mg cytisine dose using the commercial 25-day titration schedule + behavioral support</description>
          </group>
          <group group_id="O2">
            <title>3.0 mg Cytisine, Commercial Schedule</title>
            <description>3.0 mg cytisine dose using the commercial 25-day titration schedule + behavioral support</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Commercial Schedule</title>
            <description>Placebo tablets using the commercial 25-day titration schedule + behavioral support</description>
          </group>
          <group group_id="O4">
            <title>1.5 mg Cytisine, TID Schedule</title>
            <description>1.5 mg cytisine dose for 25 days using a simplified TID schedule + behavioral support</description>
          </group>
          <group group_id="O5">
            <title>3.0 mg Cytisine, TID Schedule</title>
            <description>3.0 mg cytisine dose for 25 days using a simplified TID schedule + behavioral support</description>
          </group>
          <group group_id="O6">
            <title>Placebo, TID Schedule</title>
            <description>Placebo tablets for 25 days using a simplified TID schedule + behavioral support</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Efficacy Analysis of Primary Outcome Measure: Percentage of Expected Cigarettes Smoked Per Participant During Study Treatment</title>
          <description>The daily cigarette counts (number of cigarettes smoked in the past 24 hours) were self-reported by participants in the diary. Percentage of expected cigarettes smoked was computed for each participant at the end of treatment (cigarette score), based on daily cigarette counts during treatment vs the screening period. The percentage of expected cigarettes smoked was computed as Y = (100 x N) / (T x R) where N represents total number of cigarettes smoked each day over the treatment period from Day 1 to Day 25; T represents number of post-randomization days where number of cigarettes smoked is recorded; and R represents the average number of cigarettes smoked daily over the 7-day screening period as baseline. T*R represents the total number of cigarettes that would have been smoked without intervention over the number of recorded days. Separate statistical analyses were performed for the two cytisine administration schedules (commercial and TID).</description>
          <units>percentage of cigarettes smoked</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.62" spread="3.085"/>
                    <measurement group_id="O2" value="25.04" spread="3.123"/>
                    <measurement group_id="O3" value="47.10" spread="4.417"/>
                    <measurement group_id="O4" value="29.40" spread="3.046"/>
                    <measurement group_id="O5" value="32.50" spread="3.105"/>
                    <measurement group_id="O6" value="35.30" spread="4.392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>Based on analysis of variance models with percent of expected cigarettes smoked as the dependent variable, treatment and body mass index class as main fixed effects, with covariate of baseline cigarettes.</p_value_desc>
            <method>ANOVA</method>
            <param_type>LS Mean Difference vs. Placebo</param_type>
            <param_value>-20.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.141</ci_lower_limit>
            <ci_upper_limit>-9.821</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Based on analysis of variance models with percent of expected cigarettes smoked as the dependent variable, treatment and body mass index class as main fixed effects, with covariate of baseline cigarettes.</p_value_desc>
            <method>ANOVA</method>
            <param_type>LS Mean Difference vs. Placebo</param_type>
            <param_value>-22.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.791</ci_lower_limit>
            <ci_upper_limit>-11.342</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2708</p_value>
            <p_value_desc>Based on analysis of variance models with percent of expected cigarettes smoked as the dependent variable, treatment and body mass index class as main fixed effects, with covariate of baseline cigarettes.</p_value_desc>
            <method>ANOVA</method>
            <param_type>LS Mean Difference vs. Placebo</param_type>
            <param_value>-5.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.463</ci_lower_limit>
            <ci_upper_limit>4.660</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6018</p_value>
            <p_value_desc>Based on analysis of variance models with percent of expected cigarettes smoked as the dependent variable, treatment and body mass index class as main fixed effects, with covariate of baseline cigarettes.</p_value_desc>
            <method>ANOVA</method>
            <param_type>LS Mean Difference vs. Placebo</param_type>
            <param_value>-2.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.438</ci_lower_limit>
            <ci_upper_limit>7.820</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1025</p_value>
            <p_value_desc>Based on analysis of variance models with percent of expected cigarettes smoked as the dependent variable, treatment and body mass index class as main fixed effects, with covariate of baseline cigarettes.</p_value_desc>
            <method>ANOVA</method>
            <param_type>LS Mean Difference vs. Commercial Sched.</param_type>
            <param_value>-12.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.869</ci_lower_limit>
            <ci_upper_limit>2.535</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sensitivity Analysis of Primary Outcome Measure: Analysis for Percentage of Expected Cigarettes Smoked Versus Pooled Placebo Arms, Commercial Schedule</title>
        <description>The daily cigarette counts (number of cigarettes smoked in the past 24 hours) were self-reported by participants in the diary. Percentage of expected cigarettes smoked was computed for each participant at the end of treatment (cigarette score), based on daily cigarette counts during treatment vs the screening period. (See Outcome Measure 1 description for details.) The sensitivity analysis of the primary outcome measure was only performed if results of &quot;Statistical Analysis 5&quot; for Outcome Measure 1 demonstrated the placebo treatment arms (commercial and TID) were not significantly different, and so could be pooled. Separate statistical analyses were performed for the two cytisine administration schedules (commercial and TID).</description>
        <time_frame>Day 1 through Day 25</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg Cytisine, Commercial Schedule</title>
            <description>1.5 mg cytisine dose using the commercial 25-day titration schedule + behavioral support</description>
          </group>
          <group group_id="O2">
            <title>3.0 mg Cytisine, Commercial Schedule</title>
            <description>3.0 mg cytisine dose using the commercial 25-day titration schedule + behavioral support</description>
          </group>
          <group group_id="O3">
            <title>Pooled Placebo</title>
            <description>Placebo tablets using the commercial 25-day titration schedule + behavioral support pooled with Placebo tablets for 25 days using a simplified TID schedule + behavioral support</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity Analysis of Primary Outcome Measure: Analysis for Percentage of Expected Cigarettes Smoked Versus Pooled Placebo Arms, Commercial Schedule</title>
          <description>The daily cigarette counts (number of cigarettes smoked in the past 24 hours) were self-reported by participants in the diary. Percentage of expected cigarettes smoked was computed for each participant at the end of treatment (cigarette score), based on daily cigarette counts during treatment vs the screening period. (See Outcome Measure 1 description for details.) The sensitivity analysis of the primary outcome measure was only performed if results of &quot;Statistical Analysis 5&quot; for Outcome Measure 1 demonstrated the placebo treatment arms (commercial and TID) were not significantly different, and so could be pooled. Separate statistical analyses were performed for the two cytisine administration schedules (commercial and TID).</description>
          <units>percentage of expected cigarettes smoked</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.68" spread="3.065"/>
                    <measurement group_id="O2" value="25.08" spread="3.100"/>
                    <measurement group_id="O3" value="41.29" spread="3.099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0010</p_value>
            <p_value_desc>Based on analysis of variance models with percent of expected cigarettes smoked as the dependent variable, treatment and body mass index class as main fixed effects, with covariate of baseline cigarettes.</p_value_desc>
            <method>ANOVA</method>
            <param_type>LS Mean Difference vs. Placebo</param_type>
            <param_value>-14.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.216</ci_lower_limit>
            <ci_upper_limit>-6.009</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <p_value_desc>Based on analysis of variance models with percent of expected cigarettes smoked as the dependent variable, treatment and body mass index class as main fixed effects, with covariate of baseline cigarettes.</p_value_desc>
            <method>ANOVA</method>
            <param_type>LS Mean Difference vs. Placebo</param_type>
            <param_value>-16.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.862</ci_lower_limit>
            <ci_upper_limit>-7.548</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sensitivity Analysis of Primary Outcome Measure: Analysis for Percentage of Expected Cigarettes Smoked Versus Pooled Placebo Arms, TID Schedule</title>
        <description>The daily cigarette counts (number of cigarettes smoked in the past 24 hours) were self-reported by participants in the diary. Percentage of expected cigarettes smoked was computed for each participant at the end of treatment (cigarette score), based on daily cigarette counts during treatment vs the screening period. (See Outcome Measure 1 description for details.) The sensitivity analysis of the primary outcome measure was only performed if results of &quot;Statistical Analysis 5&quot; for Outcome Measure 1 demonstrated the placebo treatment arms (commercial and TID) were not significantly different, and so could be pooled. Separate statistical analyses were performed for the two cytisine administration schedules (commercial and TID).</description>
        <time_frame>Day 1 through Day 25</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1.5 mg Cytisine, TID Schedule</title>
            <description>1.5 mg cytisine dose for 25 days using a simplified TID schedule + behavioral support</description>
          </group>
          <group group_id="O2">
            <title>3.0 mg Cytisine, TID Schedule</title>
            <description>3.0 mg cytisine dose for 25 days using a simplified TID schedule + behavioral support</description>
          </group>
          <group group_id="O3">
            <title>Pooled Placebo</title>
            <description>Placebo tablets using the commercial 25-day titration schedule + behavioral support pooled with Placebo tablets for 25 days using a simplified TID schedule + behavioral support</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity Analysis of Primary Outcome Measure: Analysis for Percentage of Expected Cigarettes Smoked Versus Pooled Placebo Arms, TID Schedule</title>
          <description>The daily cigarette counts (number of cigarettes smoked in the past 24 hours) were self-reported by participants in the diary. Percentage of expected cigarettes smoked was computed for each participant at the end of treatment (cigarette score), based on daily cigarette counts during treatment vs the screening period. (See Outcome Measure 1 description for details.) The sensitivity analysis of the primary outcome measure was only performed if results of &quot;Statistical Analysis 5&quot; for Outcome Measure 1 demonstrated the placebo treatment arms (commercial and TID) were not significantly different, and so could be pooled. Separate statistical analyses were performed for the two cytisine administration schedules (commercial and TID).</description>
          <units>percentage of expected cigarettes smoked</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.29" spread="3.291"/>
                    <measurement group_id="O2" value="32.41" spread="3.355"/>
                    <measurement group_id="O3" value="41.71" spread="3.358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0091</p_value>
            <p_value_desc>Based on analysis of variance models with percent of expected cigarettes smoked as the dependent variable, treatment and body mass index class as main fixed effects, with covariate of baseline cigarettes.</p_value_desc>
            <method>ANOVA</method>
            <param_type>LS Mean Difference vs. Placebo</param_type>
            <param_value>-12.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.695</ci_lower_limit>
            <ci_upper_limit>-3.135</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0518</p_value>
            <p_value_desc>Based on analysis of variance models with percent of expected cigarettes smoked as the dependent variable, treatment and body mass index class as main fixed effects, with covariate of baseline cigarettes.</p_value_desc>
            <method>ANOVA</method>
            <param_type>LS Mean Difference vs. Placebo</param_type>
            <param_value>-9.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.667</ci_lower_limit>
            <ci_upper_limit>0.075</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From 1st dose of study drug through Week 8 (± 3 days) post-randomization</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1.5 mg Cytisine, Commercial Schedule</title>
          <description>1.5 mg cytisine dose using the commercial 25-day titration schedule + behavioral support</description>
        </group>
        <group group_id="E2">
          <title>3.0 mg Cytisine, Commercial Schedule</title>
          <description>3.0 mg cytisine dose using the commercial 25-day titration schedule + behavioral support</description>
        </group>
        <group group_id="E3">
          <title>Placebo, Commercial Schedule</title>
          <description>Placebo tablets using the commercial 25-day titration schedule + behavioral support</description>
        </group>
        <group group_id="E4">
          <title>1.5 mg Cytisine, TID Schedule</title>
          <description>1.5 mg cytisine dose for 25 days using a simplified TID schedule + behavioral support</description>
        </group>
        <group group_id="E5">
          <title>3.0 mg Cytisine, TID Schedule</title>
          <description>3.0 mg cytisine dose for 25 days using a simplified TID schedule + behavioral support</description>
        </group>
        <group group_id="E6">
          <title>Placebo, TID Schedule</title>
          <description>Placebo tablets for 25 days using a simplified TID schedule + behavioral support</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal Investigators are bound by requirements outlined in their individual clinical trial agreements with regard to publication of trial results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Daniel Cain, Vice President, Clinical Research</name_or_title>
      <organization>Achieve Life Sciences</organization>
      <phone>425.686.1546</phone>
      <email>dcain@achievelifesciences.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

